NasdaqCM - Delayed Quote • USD
Cerevel Therapeutics Holdings, Inc. (CERE)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:26 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 9 | 8 |
| Avg. Estimate | -0.61 | -0.6 | -2.49 | -2.81 |
| Low Estimate | -0.76 | -0.73 | -2.97 | -3.29 |
| High Estimate | -0.49 | -0.38 | -1.4 | -2.18 |
| Year Ago EPS | -0.67 | -0.63 | -2.67 | -2.49 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 9 | 8 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.67 | -0.65 | -0.63 | -0.59 |
| EPS Actual | -0.67 | -0.63 | -0.61 | -0.76 |
| Difference | 0 | 0.02 | 0.02 | -0.17 |
| Surprise % | 0.00% | 3.10% | 3.20% | -28.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.61 | -0.6 | -2.49 | -2.81 |
| 7 Days Ago | -0.61 | -0.6 | -2.49 | -2.81 |
| 30 Days Ago | -0.61 | -0.6 | -2.49 | -2.79 |
| 60 Days Ago | -0.59 | -0.59 | -2.63 | -2.83 |
| 90 Days Ago | -0.59 | -0.59 | -2.63 | -2.83 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | 1 | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CERE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 9.00% | -- | -- | 5.40% |
| Next Qtr. | 4.80% | -- | -- | 10.90% |
| Current Year | 6.70% | -- | -- | 4.50% |
| Next Year | -12.90% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Mizuho: Neutral to Neutral | 2/16/2024 |
| Maintains | JP Morgan: Neutral to Neutral | 12/28/2023 |
| Downgrade | Jefferies: Buy to Hold | 12/22/2023 |
| Downgrade | TD Cowen: Outperform to Market Perform | 12/8/2023 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 12/7/2023 |
| Downgrade | Piper Sandler: Overweight to Neutral | 12/7/2023 |
Related Tickers
FUSN Fusion Pharmaceuticals Inc.
21.42
+0.09%
LABP Landos Biopharma, Inc.
22.31
-0.18%
SWTX SpringWorks Therapeutics, Inc.
45.53
+3.01%
MOR MorphoSys AG
18.04
-0.50%
MRUS Merus N.V.
45.04
+0.24%
IMTX Immatics N.V.
10.01
+2.35%
CNTA Centessa Pharmaceuticals plc
8.92
-0.11%
LEGN Legend Biotech Corporation
45.30
+1.98%
ALPN Alpine Immune Sciences, Inc.
64.56
-0.09%
IGMS IGM Biosciences, Inc.
9.40
+22.88%